It hasn’t been a smooth year for the two pharma giants, but events in the fourth quarter widened the gap between them.

Following billionaire investors isn't as difficult as you might imagine thanks to quarterly reporting required by the ...

Given its low valuation and the seeming overreaction in the markets to the recent trial results, this is a stock that could ...

Nordic firms have outperformed those from the rest of Europe over the past decade. In all four countries, listed ...

Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of ...

Pharmaceutical stalwart Novo Nordisk (NVO) can’t seem to get anything good going these days. As TipRanks’ Vince Condarcuri ...

Whether this year’s big job commitments sink or swim will be known in time. But for now, let’s explore the dreams.

Whether this year’s big job commitments sink or swim will be known in time. But for now, let’s explore the dreams.

We came across a bullish thesis on Novo Nordisk A/S (NYSE:NVO) on Kontra Investments’ Substack by Kontra. In this article, we ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Following rapid (and pricey) expansion efforts from Novo and Lilly, plus recent shortage updates at the FDA, “positive ...